Cargando…

Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study

Background. Nosocomial pneumonia due to carbapenem-resistant Gram-negative bacteria (CRGNB) is a growing concern because treatment options are limited and the mortality rate is high. The effect of tigecycline (TGC) on nosocomial pneumonia due to CRGNB in patients who have received inappropriate init...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiaomai, Zhu, Yefei, Chen, Qiuying, Gong, Liuyang, Lin, Jian, Lv, Dongqing, Feng, Jiaxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5164885/ https://www.ncbi.nlm.nih.gov/pubmed/28044137 http://dx.doi.org/10.1155/2016/8395268

Ejemplares similares

Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria
por: Wang, Qin, et al.
Publicado: (2023)

Clinical outcome of nosocomial pneumonia caused by Carbapenem-resistant gram-negative bacteria in critically ill patients: a multicenter retrospective observational study
por: Chen, Chih-Yu, et al.
Publicado: (2022)

High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study
por: Geng, Ting-Ting, et al.
Publicado: (2018)

Emergence of carbapenem resistance in Gram-negative nosocomial bloodstream infections among critically ill children? A single-center experience
por: Sasidaran, K, et al.
Publicado: (2012)

Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria
por: Deng, Tian, et al.
Publicado: (2022)

Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
por: Nordmann, Patrice, et al.
Publicado: (2019)

Global Threat of Carbapenem-Resistant Gram-Negative Bacteria
por: Jean, Shio-Shin, et al.
Publicado: (2022)

Effectiveness of a double-carbapenem combinations against carbapenem-resistant Gram-negative bacteria
por: Lu, Jiayue, et al.
Publicado: (2022)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Editorial: The global threat of carbapenem-resistant gram-negative bacteria
por: Dropa, Milena, et al.
Publicado: (2022)

Tigecycline use in serious nosocomial infections: a drug use evaluation
por: Bassetti, Matteo, et al.
Publicado: (2010)

Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline
por: Wadi, Jamal Ahmad, et al.
Publicado: (2007)

Clinical Impact of Colonization with Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Admitted for Severe Trauma
por: Ceccarelli, Giancarlo, et al.
Publicado: (2022)

Emergence of Carbapenem- and Tigecycline-Resistant Proteus cibarius of Animal Origin
por: Li, Yan, et al.
Publicado: (2020)

Clinical efficacy and safety of tigecycline based on therapeutic drug monitoring for carbapenem-resistant Gram-negative bacterium pneumonia in intensive care units
por: Bai, Xiang-rong, et al.
Publicado: (2023)

The Challenge of Overcoming Antibiotic Resistance in Carbapenem-Resistant Gram-Negative Bacteria: “Attack on Titan”
por: Mancuso, Giuseppe, et al.
Publicado: (2023)

Synthetic Teichoic Acid Conjugate Vaccine against Nosocomial Gram-Positive Bacteria
por: Laverde, Diana, et al.
Publicado: (2014)

The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016
por: Decousser, Jean-Winoc, et al.
Publicado: (2018)

Molecular epidemiology & therapeutic options of carbapenem-resistant Gram-negative bacteria
por: Garg, Atul, et al.
Publicado: (2019)

Polymyxin B/Tigecycline Combination vs. Polymyxin B or Tigecycline Alone for the Treatment of Hospital-Acquired Pneumonia Caused by Carbapenem-Resistant Enterobacteriaceae or Carbapenem-Resistant Acinetobacter baumannii
por: Chang, Kang, et al.
Publicado: (2022)

Inhalation with intravenous loading dose of colistin in critically ill patients with pneumonia caused by carbapenem-resistant gram-negative bacteria
por: Choe, Junsu, et al.
Publicado: (2019)

Benzydamine Reverses TMexCD-TOprJ-Mediated High-Level Tigecycline Resistance in Gram-Negative Bacteria
por: Tong, Ziwen, et al.
Publicado: (2021)

Evaluating the performance characteristics of different antimicrobial susceptibility testing methodologies for testing susceptibility of gram-negative bacteria to tigecycline
por: Babaei, Sima, et al.
Publicado: (2021)

Recurrence of Gram-negative nosocomial pneumonia in the critically ill patient following short-course antibiotic therapy
por: Pugh, Richard, et al.
Publicado: (2007)

Risk factors with the development of infection with tigecycline- and carbapenem-resistant Enterobacter cloacae
por: Jiang, Yuansu, et al.
Publicado: (2019)

Evaluating the Efficacies of Carbapenem/β-Lactamase Inhibitors Against Carbapenem-Resistant Gram-Negative Bacteria in vitro and in vivo
por: El Hafi, Bassam, et al.
Publicado: (2019)

The threat of carbapenem-resistant gram-negative bacteria in a Middle East region
por: Davoudi-Monfared, Effat, et al.
Publicado: (2018)

Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates
por: Schultze, Tilman G., et al.
Publicado: (2021)

Carbapenem Resistance in Gram-Negative Bacteria: A Hospital-Based Study in Egypt
por: Elrahem, Amira Abd, et al.
Publicado: (2023)

Editorial: The global threat of carbapenem-resistant gram-negative bacteria, volume II
por: Daoud, Ziad, et al.
Publicado: (2023)

Resensitizing multidrug-resistant Gram-negative bacteria to carbapenems and colistin using disulfiram
por: Chen, Chen, et al.
Publicado: (2023)

Predictors of Mortality in Patients with Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
por: Rivera-Villegas, Hector Orlando, et al.
Publicado: (2023)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
por: Chiotos, Kathleen, et al.
Publicado: (2017)

Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis
por: Oliveira, Priscila R., et al.
Publicado: (2020)

Molecular epidemiology and mechanisms of tigecycline resistance in carbapenem‐resistant Klebsiella pneumoniae isolates
por: Park, Yumi, et al.
Publicado: (2020)

Comparative Evaluation of Seven Tigecycline Susceptibility Testing Methods for Carbapenem-Resistant Enterobacteriaceae
por: Li, Hongling, et al.
Publicado: (2021)

Genetic and virulence characteristics of a Raoultella planticola isolate resistant to carbapenem and tigecycline
por: Li, Ying, et al.
Publicado: (2022)

Antimicrobial Resistance in Nosocomial Isolates of Gram-Negative Bacteria: Public Health Implications in the Latvian Context
por: Jain, Nityanand, et al.
Publicado: (2021)

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
por: Stefani, Stefania, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rjt8j1u8rg7aas17uguuerjb0r